Free Trial
→ Trump goes 'all-in' on Grand Canyon energy breakthrough (From Behind the Markets) (Ad)tc pixel Free BVXP Stock Alerts

Bioventix (BVXP) Competitors

Bioventix logo
GBX 1,706 +21.00 (+1.25%)
As of 12:27 PM Eastern
Compare

BVXP vs. AGY, BXP, ANCR, VLG, and ORPH

Should you buy Bioventix stock or one of its competitors? Bioventix's main competitors and comparable companies include Allergy Therapeutics (AGY), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Venture Life Group (VLG), and Open Orphan (ORPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bioventix compare to Allergy Therapeutics?

Allergy Therapeutics (LON:AGY) and Bioventix (LON:BVXP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Allergy Therapeutics' average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
Bioventix Neutral

Bioventix has a net margin of 59.30% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Bioventix's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Bioventix 59.30%65.83%54.07%

Allergy Therapeutics has a beta of 0.835, meaning that its share price is 17% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.555, meaning that its share price is 45% less volatile than the broader market.

0.0% of Allergy Therapeutics shares are held by institutional investors. Comparatively, 20.6% of Bioventix shares are held by institutional investors. 3.6% of Allergy Therapeutics shares are held by company insiders. Comparatively, 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Bioventix has lower revenue, but higher earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M5.33-£52.59M-£0.97N/A
Bioventix£12.54M7.02£8.12M£140.5211.99

Summary

Bioventix beats Allergy Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Bioventix compare to Beximco Pharmaceuticals?

Bioventix (LON:BVXP) and Beximco Pharmaceuticals (LON:BXP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Beximco Pharmaceuticals has higher revenue and earnings than Bioventix. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.54M7.02£8.12M£140.5211.99
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousand0.03

20.6% of Bioventix shares are held by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are held by institutional investors. 6.2% of Bioventix shares are held by insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bioventix has a beta of 0.555, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Beximco Pharmaceuticals has a beta of 0.248, meaning that its stock price is 75% less volatile than the broader market.

In the previous week, Beximco Pharmaceuticals had 1 more articles in the media than Bioventix. MarketBeat recorded 1 mentions for Beximco Pharmaceuticals and 0 mentions for Bioventix. Beximco Pharmaceuticals' average media sentiment score of 0.08 beat Bioventix's score of 0.00 indicating that Beximco Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Bioventix Neutral
Beximco Pharmaceuticals Neutral

Bioventix has a net margin of 59.30% compared to Beximco Pharmaceuticals' net margin of 16.04%. Bioventix's return on equity of 65.83% beat Beximco Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix59.30% 65.83% 54.07%
Beximco Pharmaceuticals 16.04%15.25%6.97%

Summary

Bioventix beats Beximco Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Bioventix compare to Animalcare Group?

Bioventix (LON:BVXP) and Animalcare Group (LON:ANCR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

20.6% of Bioventix shares are owned by institutional investors. Comparatively, 14.3% of Animalcare Group shares are owned by institutional investors. 6.2% of Bioventix shares are owned by company insiders. Comparatively, 30.1% of Animalcare Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Bioventix's average media sentiment score of 0.00 equaled Animalcare Group'saverage media sentiment score.

Company Overall Sentiment
Bioventix Neutral
Animalcare Group Neutral

Bioventix has a beta of 0.555, indicating that its share price is 45% less volatile than the broader market. Comparatively, Animalcare Group has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

Bioventix has a net margin of 59.30% compared to Animalcare Group's net margin of 5.70%. Bioventix's return on equity of 65.83% beat Animalcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix59.30% 65.83% 54.07%
Animalcare Group 5.70%4.46%2.97%

Bioventix pays an annual dividend of GBX 150 per share and has a dividend yield of 8.9%. Animalcare Group pays an annual dividend of GBX 5.20 per share and has a dividend yield of 1.6%. Bioventix pays out 106.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Animalcare Group pays out 71.2% of its earnings in the form of a dividend.

Animalcare Group has higher revenue and earnings than Bioventix. Bioventix is trading at a lower price-to-earnings ratio than Animalcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.54M7.02£8.12M£140.5211.99
Animalcare Group£89.11M2.60£36.55M£7.3045.89

Summary

Bioventix beats Animalcare Group on 7 of the 13 factors compared between the two stocks.

How does Bioventix compare to Venture Life Group?

Venture Life Group (LON:VLG) and Bioventix (LON:BVXP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, Venture Life Group had 9 more articles in the media than Bioventix. MarketBeat recorded 9 mentions for Venture Life Group and 0 mentions for Bioventix. Venture Life Group's average media sentiment score of 1.22 beat Bioventix's score of 0.00 indicating that Venture Life Group is being referred to more favorably in the media.

Company Overall Sentiment
Venture Life Group Positive
Bioventix Neutral

21.9% of Venture Life Group shares are owned by institutional investors. Comparatively, 20.6% of Bioventix shares are owned by institutional investors. 7.5% of Venture Life Group shares are owned by company insiders. Comparatively, 6.2% of Bioventix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Bioventix has a net margin of 59.30% compared to Venture Life Group's net margin of 17.42%. Bioventix's return on equity of 65.83% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Venture Life Group17.42% 7.82% 1.56%
Bioventix 59.30%65.83%54.07%

Venture Life Group has a beta of 0.234, meaning that its share price is 77% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.555, meaning that its share price is 45% less volatile than the broader market.

Bioventix has lower revenue, but higher earnings than Venture Life Group. Bioventix is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venture Life Group£35.17M2.39£747.21K£4.3716.02
Bioventix£12.54M7.02£8.12M£140.5211.99

Summary

Bioventix beats Venture Life Group on 7 of the 13 factors compared between the two stocks.

How does Bioventix compare to Open Orphan?

Open Orphan (LON:ORPH) and Bioventix (LON:BVXP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Bioventix has a net margin of 59.30% compared to Open Orphan's net margin of 0.00%. Bioventix's return on equity of 65.83% beat Open Orphan's return on equity.

Company Net Margins Return on Equity Return on Assets
Open OrphanN/A N/A N/A
Bioventix 59.30%65.83%54.07%

Bioventix has lower revenue, but higher earnings than Open Orphan.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Open Orphan£34.71M0.00N/AN/AN/A
Bioventix£12.54M7.02£8.12M£140.5211.99

In the previous week, Open Orphan's average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score.

Company Overall Sentiment
Open Orphan Neutral
Bioventix Neutral

20.6% of Bioventix shares are held by institutional investors. 6.2% of Bioventix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Bioventix beats Open Orphan on 6 of the 7 factors compared between the two stocks.

Get Bioventix News Delivered to You Automatically

Sign up to receive the latest news and ratings for BVXP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BVXP vs. The Competition

Export
MetricBioventixPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£89.14M£12.20B£7.11B£2.83B
Dividend Yield8.96%2.65%2.54%6.26%
P/E Ratio12.14799.73274.02366.37
Price / Sales7.11841.77595.4389,071.63
Price / Cash30.8915.0827.2227.89
Price / Book7.4210.8311.176.96
Net Income£8.12M£2.84B£3.49B£5.89B
7 Day Performance3.39%-2.22%-2.08%-0.62%
1 Month Performance2.77%-6.94%-6.80%-1.07%
1 Year Performance-29.56%-4.93%5.94%22.84%

Bioventix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BVXP
Bioventix
N/AGBX 1,706
+1.2%		N/A-30.9%£89.14M£12.54M12.1412
AGY
Allergy Therapeutics
N/AGBX 5
+5.0%		N/A-43.2%£316.63M£57.29MN/A612
BXP
Beximco Pharmaceuticals
N/AGBX 53.99
0.0%		N/A+28.2%£240.86M£53.93B0.035,500
ANCR
Animalcare Group
N/AGBX 335
flat		N/AN/A£231.30M£89.11M45.89220
VLG
Venture Life Group
N/AGBX 69.41
+1.3%		N/A+27.3%£83.33M£35.17M15.88165

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BVXP) was last updated on 10/6/2026 by MarketBeat.com Staff.
From Our Partners
Nvidia’s record quarter could send this new type of AI soaring
Nvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...
Brownstone Research | Sponsoredtc pixel
They're not telling you how bad this could get
Valuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...
Parkview Capital Group | Sponsoredtc pixel
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
This smart glasses tech is bringing the screen to your eyes
Global AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...
The Tomorrow Investor | Sponsoredtc pixel
Feds Say Your Cash Isn’t Property—Can They Take It?
The Department of Justice recently argued in court that cash may not qualify as legal property. That raises...
Priority Gold | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel